Table 2 Characteristics of the diet consumed at baseline and 12 weeks, by group
From: The role of soluble fiber intake in patients under highly effective lipid-lowering therapy
RSV+Fib | RSV | SIM/EZE+Fib | SIM+EZE | P-value | |
|---|---|---|---|---|---|
N = 28 | N = 30 | N = 28 | n = 30 | ||
MUFA%1 | |||||
Baseline | 13.8 (0.7) | 12.8 (0.7) | 13.4 (1.0) | 11.8 (0.7) | 0.374 |
12 weeks | 12.9 (0.6) | 13.6 (0.8) | 13.4 (0.5) | 11.5 (0.6) | 0.094 |
PUFA%1 | |||||
Baseline | 9.1 (0.6) | 11.9 (1.0) | 10.3 (0.8) | 10.3 (1.0) | 0.329 |
12 weeks | 8.3 (0.8) | 10.7 (1.1) | 9.6 (0.6) | 8.2 (0.7) | 0.098 |
SAFA%1 | |||||
Baseline | 9.7 (0.6) | 9.5 (0.6) | 9.5 (0.5) | 9.1 (0.6) | 0.833 |
12 weeks | 9.3 (0.5) | 9.4 (0.5) | 9.5 (0.7) | 8.9 (0.7) | 0.717 |
Trans FA%1 | |||||
Baseline | 0.3 (0.1) | 0.4 (0.1) | 0.3 (0.1) | 0.3 (0.1) | 0.608 |
12 weeks | 0.3 (0.1) | 0.4 (0.1) | 0.4 (0.2) | 0.4 (0.1) | 0.237 |
Energy Kcal/day2 | |||||
Baseline | 1762 (116) | 1766 (100) | 1828 (156) | 1741 (136) | 0.001a |
12 weeks | 1653 (116) | 1520 (85) | 1585 (129) | 1599 (102) | 0.990b |
Lipids%1 | |||||
Baseline | 36.1 (1.4) | 37.3 (1.9) | 36.3 (1.7) | 34.3 (1.8) | 0.941 |
12 weeks | 33.9 (1.4) | 36.9 (1.8) | 35.7 (1.2) | 31.4 (1.6) | 0.041 |
Carbohydrates%1 | |||||
Baseline | 46.4 (1.9) | 46.9 (2.1) | 46.7 (2.3) | 49.2 (2.1) | 0.869 |
12 weeks | 46.3 (1.5) | 46.5 (1.6) | 46.7 (1.7) | 52.1 (1.8) | 0.034 |
Proteins%1 | |||||
Baseline | 18 (1.3) | 16.5 (1.0) | 17.7 (1.3) | 17.3 (0.9) | 0.79 |
12 weeks | 20 (1.0) | 17.6 (0.9) | 18.5 (1.2) | 17.8 (0.8) | 0.268 |
Cholesterol mg/day2 | |||||
Baseline | 214 (29) | 200 (21) | 197 (33) | 210 (29) | 0.203a |
12 weeks | 222 (29) | 157 (12) | 201 (34) | 171 (22) | 0.683b |
Fibers g/day2 | |||||
Baseline | 20 (3) | 17 (1) | 22 (3) | 16 (2) | 0.853a |
12 weeks | 20 (2) | 16 (1) | 18 (2) | 19 (2) | 0.666a |